DiaMedica Therapeutics Inc. - 8-K Filing

DiaMedica Therapeutics reports Q3 2026 results with $34.9M cash position and clinical updates for DM199 programs. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $DMAC

Read the full article at SEC EDGAR

More Regulatory news